Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Capricor Therapeutics, Inc.CAPR · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $355.9M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Mar 17, 2026206 days before the rescan; every figure keyed to the SEC receipt date
Last close$8.012026-10-08; market equity $465.4M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$20NovDecJanFebMarAprMayJunJulAugSepOct$8.01
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2012nonen/aQ1
Mar 21, 2015nonen/aQ2
Apr 21, 2019nonen/aQ1
Mar 21, 2021nonen/aQ2
Apr 21, 2025nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 17, 2026; the document on sec.gov.

Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 25.9%[3-4]
Short runway. cash runway is 2.4 months[5]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 33.0
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(13.4%)[1,6-8](6.6%)33.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 16.8
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime6.86[1,9-14](0.31)14.77562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio9.01x[9-10]2.96x19.08392025-12-31
Growth and financing, sleeve percentile 34.1
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years92.2%[1,8,15-16]2.1%2.67042025-12-31
Net share issuance, one year25.9%[3-4]2.5%65.76342026-03-16

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month37.4%8.0%70hotter than 70 of 100 peers
Distance from 52-week high(77.3%)(31.4%)9closer to its high than 9 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(15.6%)(1.0%)25pricier than 75 of 100 peers
Book value to price0.530.2871pricier than 29 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years93.6%20.3%77more equity-funded than 77 of 100 peers
Relative strength against the sector, log excess return0.11(0.14)70ahead of 70 of 100 peers

Inputs: market equity $465.7M; EBIT -$108.1M; free cash flow -$72.7M; book equity $246.2M; sales $0; cash $20.9M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(61.6%)✗ fail[6,8]
Operating cash flow above zero-$69.8M✗ fail[7]
Return on assets improved7.3 pts✓ pass[6,8,15,18]
Operating cash flow exceeds net income$35.2M✓ pass[6-7]
Long-term leverage felln/a[1,8,15]
Current ratio improved124.1 pts✓ pass[9-10,19-20]
No new shares issued25.9%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved(37.9 pts)✗ fail[2,8,15,21]
Cash, filings, liquidity
Cash and equivalents$20.9M[5]
Operating cash flow, four quarters-$104.0M[5,7,22-25]
Months of runway2.4
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$27.9M
63 sessions
Days since newest grade input206

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$355.9M2025-12-312026-03-1710-Kfiling · viewer · series
2revenueus-gaap:Revenues$02025-12-312026-03-1710-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding57,510,6352026-03-162026-03-1710-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding45,676,2022025-03-242025-03-2610-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$20.9M2026-06-302026-08-1410-Qfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$105.0M2025-12-312026-03-1710-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$69.8M2025-12-312026-03-1710-Kfiling · viewer · series
8assetsus-gaap:Assets$170.5M2024-12-312026-03-1710-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$322.9M2025-12-312026-03-1710-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$35.8M2025-12-312026-03-1710-Kfiling · viewer · series
11retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$304.9M2025-12-312026-03-1710-Kfiling · viewer · series
12operating incomeus-gaap:OperatingIncomeLoss-$108.1M2025-12-312026-03-1710-Kfiling · viewer · series
13book equityus-gaap:StockholdersEquity$305.8M2025-12-312026-03-1710-Kfiling · viewer · series
14liabilitiesus-gaap:Liabilities$50.2M2025-12-312026-03-1710-Kfiling · viewer · series
15assetsus-gaap:Assets$58.7M2023-12-312025-03-2610-Kfiling · viewer · series
16assetsus-gaap:Assets$50.1M2022-12-312024-03-1110-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding58,138,9892026-08-132026-08-1410-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$40.5M2024-12-312026-03-1710-Kfiling · viewer · series
19current assetsus-gaap:AssetsCurrent$163.4M2024-12-312026-03-1710-Kfiling · viewer · series
20current liabilitiesus-gaap:LiabilitiesCurrent$21.0M2024-12-312026-03-1710-Kfiling · viewer · series
21revenueus-gaap:Revenues$22.3M2024-12-312026-03-1710-Kfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$60.7M2026-06-302026-08-1410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$29.3M2026-03-312026-05-1310-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$46.2M2025-09-302025-11-1010-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$26.6M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.